Drugs / Autologous CD8+ Melanoma Specific T Cells
Autologous CD8+ Melanoma Specific T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02027935 | Jan 2015 → Apr 2024 | cutaneous melanoma, metastatic melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD8+ Melanoma Specific T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02027935 ↗ |
| Modality | Cell therapy | “adoptively transferred cytotoxic T-lymphocytes (CTL)” NCT02027935 ↗ |
| Route | Intravenous | “Given IV” NCT02027935 ↗ |